Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (3355)	10/3/2002 7:22:02 AM
From: Icebrg	Read Replies (1) \| Respond to of 10345

Stefaan So far Elan has been lucky to find "perfect" buyers. Enzon has the ambition to become a fully integrated pharmaceutical company (just like Elan). They got not only the drug, but also manufacturing facilities and 60 salesmen. For them the deal was more than just about Abelcet. So they felt they were able to pay more. As for Actiq, this is a product that Cephalon is already selling with some success in the US. The current run rate is abt. 100 mUSD and sales are growing fast. It is natural that they also want get to the European part of the pie. And that they are prepared to pay for it. Having closed two deals on favorable terms and collected more than 400 mUSD within a couple of months should also make it possible for Elan to approach other potential buyers with more confidence As for the LYONS. Let's hope that that is the case. They should at least be able to use the 50 mUSD they get from Cephalon, as that deal seems to have closed. Ice